Navigation Links
Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
Date:7/14/2008

24-hour studies, the data were post-processed for comparison with the reference blood glucose values collected during the study periods. Data were validated for ten subjects for 12 hours in Study I, eight subjects for 24 hours in Study II and in Study III.

Analytical Methods

The primary statistical analysis tool used to evaluate the performance of the Symphony tCGM System relative to the reference measurements was the Clarke error grid, which has been widely used to evaluate the performance of glucometers. The Clarke error grid is a plot of all data pairs categorized into five discrete areas: A, B, C, D and E. The A and B areas are the most clinically desirable zones and D and E are the least clinically desirable zones. Devices with a higher combined A and B percentage (closer to 100%) and lower combined D and E percentage (closer to 0%) are considered to have better performance. Continuous Glucose Monitoring (CGM) system performance, including tCGM system performance, is generally considered acceptable if at least ninety-five percent (95%) of the data points fall within the combined A/B region, along with negligible or no data points in the combined D/E region. Mean absolute relative difference (MARD) is a standard error calculation tool that was used to measure the average relative difference between Symphony and the reference measurements, on a percentage basis. A low MARD error, below 20%, is generally accepted to be consistent with an accurate and reliable monitoring device.

Study Results

Comparing predicted glucose versus reference blood glucose values, Study I yielded 89.6% in Zone A and 9.0% in Zone B in the Clarke error grid (222 data points), Study II yielded 86.4% in Zone A and 13.6% in Zone B (147 data points), and Study III yielded 89.9% in Zone A and 10.1% in Zone B (378 data points). Each of the three studies yielded positive results, with combined A and B percentages of 98.7%, 100%, and 100% in Study I, II, and III, respec
'/>"/>

SOURCE Echo Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
2. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
3. Silence Therapeutics Announces Board Changes
4. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
5. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
6. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
7. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
8. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
9. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
10. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
11. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... WORCESTER, Mass. and TORONTO ... ( www.generex.com ) (OTCQB:GNBT) today announced that it intends ... securities it receives upon completion of a definitive licensing ... to Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). ... a non-binding letter of intent in respect of the ...
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
(Date:5/5/2015)... The PracticeMatch Career Fair will take ... at the Rochester Marriott, 1001 First Avenue SW, Rochester, MN ... opportunities will be attending from across the country. All specialties ... raffle prize drawings. , Leslie Thompson, Director of Career Fairs ... to hold a career fair. In the metropolitan area there ...
(Date:5/5/2015)... 05, 2015 The report ... provides comparative analysis on the therapeutic development ... pipelines by identifying new targets and MOAs ... report is available at http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2014-market-report.html ... Fibrosis – Pipeline Review, H2 2014 report ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 With the ... clothing and enjoying the feel of warm breezes on bare ... to strategies on how to look their best in shorts, ... “More and more people are turning to laser treatments for ... aesthetician of Simply Posh Aesthetic Spa . “They're all ...
(Date:5/5/2015)... There have been numerous attempts to ... on personal lines (home, auto, etc). Now, for the ... (NDOI.com) has created an online vehicle for more than ... present their expertise in all realms of insurance directly ... and two-fold. , First, the online, searchable database improves ...
(Date:5/4/2015)... Hoersholm, Denmark (PRWEB) May 05, 2015 ... pathology, announces today the closing of a private round ... amount is undisclosed. , This investment will assist Visiopharm ... as a market leader for image analysis driven diagnostic ... see how much Visiopharm's ONCOtopix™ Dx solution ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 3Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 3Health News:Laser Hair Removal: Tips for Summertime Grooming 2Health News:Laser Hair Removal: Tips for Summertime Grooming 3Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 3Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 2Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 3
... fears of large scale global outbreak of bird flu that ... people have started stock piling and storing stocks of bird ... and Human Services (HHS) plans to stock vaccines and anti-viral ... avian influenza has infected more than 100 people in Asia ...
... voice concerns over the use of Jab (MMR Vaccines), there ... wide which is the only source of protection for children’s ... of about 80% in the usage // of vaccine ... world wide concerns regarding the use of MMR vaccine as ...
... Exposure to lead in early childhood and adolescence may ... cognitive abilities. // , ,Both lead exposure and ... adults. The study indicates that the interaction between lead ... in working age adults may lead to diminishing cognitive ...
... Seasonal Affective Disorder (SAD) has been found to be affected ... emphasising the importance of sunlight for health. // ... a drop in physical energy, increased appetite, and increased need ... complex inter relation between melatonin and serotonin. , ,Our ...
... India has an estimated 5.1 million HIV-infected people, next only ... Shillong (capital of the northeastern state of Meghalaya.) said that ... India in three to four years., ,The northeast state ... India and the AIDS virus has now many victims in ...
... leading to a condition of early atherosclerosis, according to a ... women in the same // situation do not show ... University of Helsinki in Finland had found increased thickness of ... the head, in men who reported having low job control ...
Cached Medicine News:Health News:Increased demand for Bird flu anti-viral drug world wide 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: